

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and
February 2005

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:24:48 ON 05 JAN 2005

=> file medline, uspatful, dgene, embase, wpids
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 12:25:30 ON 05 JAN 2005

FILE 'USPATFULL' ENTERED AT 12:25:30 ON 05 JAN 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:25:30 ON 05 JAN 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 12:25:30 ON 05 JAN 2005

COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:25:30 ON 05 JAN 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

=> s insulin agonist

L1 3125 INSULIN AGONIST

=> s insulin

L2 543756 INSULIN

=> s l2 and ailment

L3 273 L2 AND AILMENT

=> s l3 and hyperglycemia

L4 43 L3 AND HYPERGLYCEMIA

=> s l3 and diabetes

L5 180 L3 AND DIABETES

=> s l4 and l5

L6 41 L4 AND L5

=> s l6 and l1

L7 0 L6 AND L1

=> s l6 and treatment

L8 40 L6 AND TREATMENT

=> s nonpeptidyl compound

L9 7 NONPEPTIDYL COMPOUND

=> s l9 and l8

L10 0 L9 AND L8

=> s l8 and agonist

L11 17 L8 AND AGONIST

=> d l11 ti abs ibib tot

L11 ANSWER 1 OF 17 USPATFULL on STN

TI Regulators of the hedgehog pathway, compositions and uses related thereto

AB The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating the consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or

small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylyate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:165984 USPATFULL
TITLE: Regulators of the hedgehog pathway, compositions and uses related thereto
INVENTOR(S): Dudek, Henryk, Wellesley, MA, UNITED STATES
Ji, Benxiu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Curis, Inc., Cambridge, MA, UNITED STATES, 02138 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004127474	A1	20040701
APPLICATION INFO.:	US 2003-735116	A1	20031212 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-867311, filed on 29 May 2001, GRANTED, Pat. No. US 6686388 Continuation of Ser. No. US 1999-417564, filed on 14 Oct 1999, GRANTED, Pat. No. US 6291516		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115642P	19990113 (60)
	US 1999-142124P	19990702 (60)
	US 1999-119594P	19990210 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 3837

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 17 USPATFULL on STN

TI Hedgehog antagonists, methods and uses related thereto
AB The present application is directed to compositions and methods for inhibiting angiogenesis and treating or preventing unwanted cell proliferation, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those disclosed herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:144991 USPATFULL
TITLE: Hedgehog antagonists, methods and uses related thereto
INVENTOR(S): Dudek, Henryk, Wellesley, MA, UNITED STATES
Karavanov, Irina, Bethesda, MD, UNITED STATES
Pepicelli, Carmen, Lowell, MA, UNITED STATES
Kotkow, Karen, Jamaica Plain, MA, UNITED STATES
Rubin, Lee L., Wellesley, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004110663	A1	20040610
APPLICATION INFO.:	US 2003-652298	A1	20030829 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-977864, filed on 15 Oct 2001, PENDING		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2000-240564P 20001013 (60)
US 2002-407145P 20020829 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA,
02110-2624
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 54 Drawing Page(s)
LINE COUNT: 7902
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 17 USPATFULL on STN

TI Growth inhibition and eradication of solid tumors using neuroendocrine
resetting therapy and photodynamic therapy
AB A method of ablating the growth of or eradicating tumors in mammals
having prolactin, growth hormone, and melatonin daily rhythms by
adjusting one or more of the prolactin, growth hormone, and melatonin
profiles of the mammal to conform to or approach the corresponding
normal profile for healthy members of the same species and sex as said
mammal, contacting the cells of the tumor with a photoactive
photosensitizer, and, exposing the photosensitizer-contacted tumor cells
to light of a predetermined wavelength, power density, and energy level.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:133846 USPATFULL
TITLE: Growth inhibition and eradication of solid tumors using
neuroendocrine resetting therapy and photodynamic
therapy
INVENTOR(S): Cincotta, Anthony H., Charlestown, MA, UNITED STATES
Cincotta, Louis, Andover, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004102383	A1	20040527
APPLICATION INFO.:	US 2003-719534	A1	20031121 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-187768, filed on 6 Nov 1998, ABANDONED Continuation of Ser. No. US 1997-838079, filed on 15 Apr 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-16619P	19960501 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1282	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 17 USPATFULL on STN

TI Hedgehog antagonists, methods and uses related thereto
AB The present application is directed to compositions and methods for
inhibiting angiogenesis and treating or preventing unwanted cell
proliferation, including tumors, by inhibiting the hedgehog pathway,
e.g., with an antagonist of the hedgehog pathway such as those disclosed
herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:80130 USPATFULL
TITLE: Hedgehog antagonists, methods and uses related thereto

INVENTOR(S): Dudek, Henryk, Wellesley, MA, UNITED STATES
Karavanov, Irina, Bethesda, MD, UNITED STATES
Pepicelli, Carmen, Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004060568	A1	20040401
APPLICATION INFO.:	US 2001-977864	A1	20011015 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240564P	20001013 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	38 Drawing Page(s)	
LINE COUNT:	5652	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 17 USPATFULL on STN

TI **Insulin**-responsive DNA binding protein-1 and methods to regulate **insulin**-responsive genes

AB The present invention relates to the novel protein **Insulin**-Responsive DNA Binding Protein-1 (IRDBP-1) and nucleotide sequences that encode it. IRDBP-1 binds to nucleic acid regions of genes that respond when cells are exposed to **insulin**. IRDBP-1 regulates genes important in mediating the **insulin** response in mammals and in regulating conditions such as **diabetes**, obesity, **insulin**-resistant syndrome and cell proliferative disorders. The present invention provides nucleic acids useful as probes for detecting nucleic acids encoding regions of the IRDBP-1 protein. Within the scope of the present invention are recombinant cells, tissues and animals containing non-naturally occurring recombinant nucleic acid molecules encoding IRDBP-1, including expression vectors, antibodies specific for IRDBP-1, assays for IRDBP-1 polypeptide, and methods relating to all of the foregoing, the development of therapeutic and diagnostic agents that mimic, facilitate or inhibit the action of IRDBP-1, and/or are based on relationships to the structure and action of IRDBP-1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181463 USPATFULL
TITLE: **Insulin**-responsive DNA binding protein-1 and methods to regulate **insulin**-responsive genes
INVENTOR(S): Villafuerte, Betty C., Atlanta, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125296	A1	20030703
APPLICATION INFO.:	US 2002-310002	A1	20021204 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-703559, filed on 1 Nov 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336585P	20011204 (60)
	US 2002-390000P	20020618 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOMBLE CARLYLE SANDRIDGE & RICE, P.O. Box 7037, Atlanta, GA, 30357-0037	
NUMBER OF CLAIMS:	77	

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 88 Drawing Page(s)
LINE COUNT: 6473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 17 USPATFULL on STN

TI Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
AB The invention features nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors as novel therapeutic agents. The invention also features a method of treating a mammal, preventing a disease or disorder, or improve health by administering nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:266291 USPATFULL
TITLE: Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
INVENTOR(S): Kopin, Alan S., Wellesley, MA, UNITED STATES
Beinborn, Martin, Boston, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002147170	A1	20021010
APPLICATION INFO.:	US 2001-39645	A1	20011025 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-243550P	20001026 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	31 Drawing Page(s)	
LINE COUNT:	2842	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 17 USPATFULL on STN

TI INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO
AB The present invention makes available assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein comprising contacting a cell sensitive to the hedgehog protein with a steroidal alkaloid, or other small molecule, in a sufficient amount to reduce the sensitivity of the cell to the hedgehog protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:12550 USPATFULL
TITLE: INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO
INVENTOR(S): BEACHY, PHILIP A., BALTIMORE, MD, UNITED STATES
COOPER, MICHAEL K., BALTIMORE, MD, UNITED STATES
PORTER, JEFFREY A., CAMBRIDGE, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002006931	A1	20020117
	US 6432970	B2	20020813
APPLICATION INFO.:	US 1998-90622	A1	19980604 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1998-81186P 19980409 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA,
02110-2624
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 3884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 17 USPATFULL on STN

TI GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING NEUROENDOCRINE
RESETTING THERAPY AND PHOTODYNAMIC THERAPY

AB A method of ablating the growth of or eradicating tumors in mammals
having prolactin, growth hormone, and melatonin daily rhythms by
adjusting one or more of the prolactin, growth hormone, and melatonin
profiles of the mammal to conform to or approach the corresponding
normal profile for healthy members of the same species and sex as said
mammal, contacting the cells of the tumor with a photoactive
photosensitizer, and, exposing the photosensitizer-contacted tumor cells
to light of a predetermined wavelength, power density, and energy level.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:224133 USPATFULL
TITLE: GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING
NEUROENDOCRINE RESETTNG THERAPY AND PHOTODYNAMIC
THERAPY
INVENTOR(S): CINCOTTA, ANTHONY H., CHARLESTOWN, MA, United States
CINCOTTA, LOUIS, ANDOVER, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001049350	A1	20011206
APPLICATION INFO.:	US 1998-187768	A1	19981106 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-838079, filed on 15 Apr 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-16619P	19960501 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DARBY & DARBY, 805 THIRD AVENUE, NEW YORK, NY, 10022	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1334	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L11 ANSWER 9 OF 17 USPATFULL on STN

TI Regulators of the hedgehog pathway, compositions and uses related
thereto

AB The present invention makes available methods and reagents for
inhibiting aberrant growth states resulting from hedgehog
gain-of-function, ptc loss-of-function or smoothened gain-of-function
comprising contacting a cell with a compound, such as a polypeptide or
small molecule in an amount sufficient to control the aberrant growth
state e.g., to agonize a normal ptc pathway or antagonize smoothened or
hedgehog activity. The present invention further makes available methods
and reagents for ameliorating to consequences of hedgehog
loss-of-function, ptc gain-of-function, or smoothened loss-of-function
comprising contacting a cell with a compound, such as a polypeptide or

small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:188704 USPATFULL
TITLE: Regulators of the hedgehog pathway, compositions and uses related thereto
INVENTOR(S): Dudek, Henryk, Wellesley, MA, United States
Ji, Benxiu, Sharon, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001034337	A1	20011025
	US 6686388	B2	20040203
APPLICATION INFO.:	US 2001-867311	A1	20010529 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-417564, filed on 14 Oct 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115642P	19990113 (60)
	US 1999-119594P	19990210 (60)
	US 1999-142124P	19990702 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	3831	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 17 USPATFULL on STN

TI Regulators of the hedgehog pathway, compositions and uses related thereto

AB The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating the consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:158338 USPATFULL
TITLE: Regulators of the hedgehog pathway, compositions and uses related thereto
INVENTOR(S): Dudek, Henryk, Wellesley, MA, United States
Ji, Benxiu, Sharon, MA, United States
PATENT ASSIGNEE(S): Curis, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6291516 B1 20010918
APPLICATION INFO.: US 1999-417564 19991014 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115642P	19990113 (60)
	US 1999-119594P	19990210 (60)
	US 1999-142124P	19990702 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Krass, Frederick	
LEGAL REPRESENTATIVE:	Vincent, Matthew P., Halstead, David P. Ropes & Gray	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 19 Drawing Page(s)	
LINE COUNT:	3730	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 17 USPATFULL on STN
TI Method of regulating immune function
AB Disclosed herein is a method of treating an immune system dysfunction in a mammal by administering a prolactin reducer and a prolactin enhancer at a predetermined time or times.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:74285 USPATFULL
TITLE: Method of regulating immune function
INVENTOR(S): Cincotta, Anthony H., Andover, MA, United States
Meier, Albert H., Andover, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Baton Rouge, LA, United States (U.S. corporation)
The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6075020		20000613
APPLICATION INFO.:	US 1998-204839		19981203 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-780727, filed on 8 Jan 1997, now patented, Pat. No. US 5872127 which is a continuation of Ser. No. US 1994-271881, filed on 7 Jul 1994, now patented, Pat. No. US 5696128		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Richter, Johann		
ASSISTANT EXAMINER:	Keys, Rosalynd		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	1326		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 17 USPATFULL on STN
TI Method for inhibiting neoplastic disease in mammals
AB This invention relates to a method for inhibiting the growth of neoplasms, in a mammal having a prolactin profile. This method involves comparing the prolactin profile of the afflicted mammal to a standard prolactin profile for healthy mammals of the same species and sex and adjusting the prolactin profile of the afflicted mammal to conform to or approach the standard prolactin profile for a mammal of the same species and sex of the afflicted mammal, thereby inhibiting the neoplastic growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:70843 USPATFULL
TITLE: Method for inhibiting neoplastic disease in mammals
INVENTOR(S): Cincotta, Anthony H., Andover, MA, United States
Meier, Albert H., Baton Rouge, LA, United States
PATENT ASSIGNEE(S): The Board of Supervisors of Louisiana State University
and Agricultural and Mechanical College, Baton Rouge,
LA, United States (U.S. corporation)
Ergo Research Corporation, Wakefield, RI, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6071914		20000606
APPLICATION INFO.:	US 1996-656103		19960531 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-475296, filed on 7 Jun 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	925		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 17 USPATFULL on STN

TI Method of treating rheumatoid arthritis
AB Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems, such as rheumatoid arthritis. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals). Additionally, methods of upregulating or augmenting an immune response in a mammal are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:59073 USPATFULL
TITLE: Method of treating rheumatoid arthritis
INVENTOR(S): Cincotta, Anthony H., Andover, MA, United States
Meier, Albert H., Andover, MA, United States
PATENT ASSIGNEE(S): Ergo Science Incorporated, Charlestown, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5905083		19990518
APPLICATION INFO.:	US 1995-459114		19950602 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Geist, Gary		
ASSISTANT EXAMINER:	Keys, Rosalynd		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	1357		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 17 USPATFULL on STN

TI Method of regulating the immune response

AB Methods for upregulating abnormal responses of the mammalian immune system are provided. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed is a method for administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:22114 USPATFULL

TITLE: Method of regulating the immune response

INVENTOR(S): Cincotta, Anthony H., Andover, MA, United States
Meier, Albert H., Andover, MA, United States

PATENT ASSIGNEE(S): The Board of Supervisors of Louisiana University and
Agricultural and Mechanical College, Baton Rouge, LA,
United States (U.S. corporation)
The General Hospital Corporation, Boston, MA, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5872133		19990216
APPLICATION INFO.:	US 1995-458960		19950602 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-271881, filed on 7 Jul 1994, now patented, Pat. No. US 5696128 And a continuation-in-part of Ser. No. US 1992-995292, filed on 22 Dec 1992, now patented, Pat. No. US 5585347		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Geist, Gary		
ASSISTANT EXAMINER:	Keys, Rosalynd		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	1400		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 17 USPATFULL on STN

TI Method of regulating immune function

AB Disclosed are methods for treating a disorder to the immune system or an immunodeficiency state which comprise the steps of administering to a patient an effective amount of at least one serotonin **agonist** and at least one dopamine **agonist**, where the combination of the serotonin **agonist** and the dopamine **agonist** are present in an amount effective to treat the patient's condition, where administration of each of the agents is confined to the time of day during which the administration is capable of adjusting the prolactin profile of the patient to conform or to approach the standard human prolactin profile.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:22108 USPATFULL

TITLE: Method of regulating immune function

INVENTOR(S): Cincotta, Anthony H., Andover, MA, United States
Meier, Albert H., Andover, MA, United States

PATENT ASSIGNEE(S): The General Hospital Corporation/Board of Supervisors
of Louisiana State University, Boston, MA, United
States (U.S. corporation)

Agricultural and Mechanical College, Baton Rouge, LA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5872127		19990216
APPLICATION INFO.:	US 1997-780727		19970108 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-271881, filed on 7 Jul 1994, now patented, Pat. No. US 5696128		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Geist, Gary		
ASSISTANT EXAMINER:	Keys, Rosalynd		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	1354		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 17 USPATFULL on STN

TI Method for inhibiting neoplastic disease in mammals
AB This invention relates to a method for inhibiting the growth of neoplasms, in a mammal having a prolactin profile. This method involves comparing the prolactin profile of the afflicted mammal to a standard prolactin profile for healthy mammals of the same species and sex and adjusting the prolactin profile of the afflicted mammal to conform to or approach the standard prolactin profile for a mammal of the same species and sex of the afflicted mammal, thereby inhibiting the neoplastic growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:95521 USPATFULL
TITLE: Method for inhibiting neoplastic disease in mammals
INVENTOR(S): Cincotta, Anthony H., Andover, MA, United States
Meier, Albert H., Baton Rouge, LA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
The Board of Supervisors of Louisiana State University and Agricultural & Mechanical College, Baton Rouge, LA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5792748		19980811
APPLICATION INFO.:	US 1995-475296		19950607 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	888		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 17 USPATFULL on STN

TI Method of regulating immune function
AB Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's

abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals). Additionally, methods of upregulating or augmenting an immune response in a mammal are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:115286 USPATFULL
TITLE: Method of regulating immune function
INVENTOR(S): Cincotta, Anthony H., Andover, MA, United States
Meier, Albert H., Andover, MA, United States
PATENT ASSIGNEE(S): The Board of Supervisors of Louisiana University and
Agricultural and Mechanical College, Baton Rouge, LA,
United States (U.S. corporation)
The General Hospital Corporation, Boston, MA, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5696128		19971209
APPLICATION INFO.:	US 1994-271881		19940707 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Conrad, Joseph		
ASSISTANT EXAMINER:	Williams, Rosalynd		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	1421		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:24:48 ON 05 JAN 2005)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 12:25:30 ON 05 JAN 2005

L1	3125 S INSULIN AGONIST
L2	543756 S INSULIN
L3	273 S L2 AND AILMENT
L4	43 S L3 AND HYPERGLYCEMIA
L5	180 S L3 AND DIABETES
L6	41 S L4 AND L5
L7	0 S L6 AND L1
L8	40 S L6 AND TREATMENT
L9	7 S NONPEPTIDYL COMPOUND
L10	0 S L9 AND L8
L11	17 S L8 AND AGONIST

=> d l9 ti abs ibib tot

L9 ANSWER 1 OF 7 USPATFULL on STN
TI Treatment of aldehyde-fixed tissue
AB A method of preparing a biological tissue for implantation that has been treated with an aldehyde, the method utilizing a cyclic nonpeptidyl amide-functional and/or imide-functional compound to remove excess aldehyde from the treated biological material, thereby detoxifying the biological tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:75330 USPATFULL
TITLE: Treatment of aldehyde-fixed tissue

INVENTOR(S): Trescony, Paul V., Champlin, MN, United States
Zilla, Peter, Cape Town, South Africa
PATENT ASSIGNEE(S): Medtronic, Inc., Minneapolis, MN, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5919472		19990706
APPLICATION INFO.:	US 1996-619843		19960319 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Shelborne, Kathryne E.		
LEGAL REPRESENTATIVE:	Patton, Harold R., Forrest, Peter		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	514		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 7 USPATFULL on STN
TI Ras farnesyl transferase inhibitors
AB Benzodiazepine derivatives represented by the structure below are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases foe which inhibition of the ras farnesyl:protein transferase as indicated.
##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:150943 USPATFULL
TITLE: Ras farnesyl transferase inhibitors
INVENTOR(S): Marsters, Jr., James C., Oakland, CA, United States
Brown, Michael S., Dallas, TX, United States
Crowley, Craig W., Portola Valley, CA, United States
Goldstein, Joseph L., Dallas, TX, United States
James, Guy L., Dallas, TX, United States
McDowell, Robert S., San Francisco, CA, United States
Oare, David, Belmont, CA, United States
Rawson, Thomas E., Mountain View, CA, United States
Reynolds, Mark, South San Francisco, CA, United States
Somers, Todd C., Foster City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)
Board of Regents University of Texas, Austin, TX,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843941		19981201
	WO 9426723		19941124
APPLICATION INFO.:	US 1994-313068		19940926 (8)
	WO 1994-US5157		19940510
			19940926 PCT 371 date
			19940926 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-82202, filed on 24 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61961, filed on 14 May 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bond, Robert T.		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1,15		

NUMBER OF DRAWINGS: 21 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 8094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 7 USPATFULL on STN

TI Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b
III.sub.a

AB A benzodiazepinedione derivative which acts as a nonpeptidyl platelet
aggregation inhibitor is provided. This inhibitor potently inhibits
fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided
in therapeutic compositions for the treatment of diseases for which
blocking platelet aggregation is indicated. These nonpeptidyl inhibitors
are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:91522 USPATFULL

TITLE: Nonpeptidyl integrin inhibitors having specificity for
the GPII.sub.b III.sub.a

INVENTOR(S): Blackburn, Brent, San Francisco, CA, United States

Barker, Peter, El Granada, CA, United States

Gadek, Thomas, Oakland, CA, United States

McDowell, Robert, San Francisco, CA, United States

McGee, Lawrence, Pacifica, CA, United States

Somers, Todd, Montara, CA, United States

Webb, Rob, Moss Beach, CA, United States

Robarge, Kirk, San Francisco, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5674865		19971007
APPLICATION INFO.:	US 1995-451794		19950526 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-70457, filed on 8 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-866931, filed on 10 Apr 1992, now patented, Pat. No. US 5250679 which is a continuation-in-part of Ser. No. US 1991-781477, filed on 18 Oct 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Wong, King Lit		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	13454		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 7 USPATFULL on STN

TI Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b
III.sub.a receptor

AB A benzodiazepinedione derivative which acts as a nonpeptidyl platelet
aggregation inhibitor is provided. This inhibitor potently inhibits
fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided
in therapeutic compositions for the treatment of diseases for which
blocking platelet aggregation is indicated. These nonpeptidyl inhibitors
are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:91520 USPATFULL

TITLE: Nonpeptidyl integrin inhibitors having specificity for
the GPII.sub.b III.sub.a receptor

INVENTOR(S): Blackburn, Brent, San Francisco, CA, United States

Barker, Peter, El Granada, CA, United States
 Gadek, Thomas, Oakland, CA, United States
 McDowell, Robert, San Francisco, CA, United States
 McGee, Lawrence, Pacifica, CA, United States
 Somers, Todd, Montara, CA, United States
 Webb, Rob, Moss Beach, CA, United States
 Robarge, Kirk, San Francisco, CA, United States
 Genentech, Inc., South San Francisco, CA, United States
 (U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5674863		19971007
APPLICATION INFO.:	US 1995-451849		19950526 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-70457, filed on 8 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-866931, filed on 10 Apr 1992, now patented, Pat. No. US 5250679 which is a continuation-in-part of Ser. No. US 1991-781477, filed on 18 Oct 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Wong, King Lit		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	13521		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L9 ANSWER 5 OF 7 USPATFULL on STN

TI Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor

AB A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:78435 USPATFULL

TITLE: Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor

INVENTOR(S): Blackburn, Brent, San Francisco, CA, United States
 Barker, Peter, El Granada, CA, United States
 Gadek, Thomas, Oakland, CA, United States
 McDowell, Robert, San Francisco, CA, United States
 McGee, Lawrence, Pacifica, CA, United States
 Somers, Todd, Montara, CA, United States
 Webb, Rob, Moss Beach, CA, United States
 Robarge, Kirk, San Francisco, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5663166		19970902
APPLICATION INFO.:	US 1995-452056		19950526 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-70457, filed on 8 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-866931, filed on 10 Apr 1992, now patented, Pat. No. US 5250679 which is a continuation-in-part of Ser. No. US 1991-781477, filed		

on 18 Oct 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bond, Robert T.
LEGAL REPRESENTATIVE: Winter, Daryl B.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 13432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 7 USPATFULL on STN
TI Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b
III.sub.a receptor
AB A benzodiazepinedione derivative which acts as a nonpeptidyl platelet
aggregation inhibitor is provided. This inhibitor potently inhibits
fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided
in therapeutic compositions for the treatment of diseases for which
blocking platelet aggregation is indicated. These nonpeptidyl inhibitors
are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:94579 USPATFULL
TITLE: Nonpeptidyl integrin inhibitors having specificity for
the GPII.sub.b III.sub.a receptor
INVENTOR(S): Blackburn, Brent, San Francisco, CA, United States
Barker, Peter, El Granada, CA, United States
Gadek, Thomas, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
McGee, Lawrence, Pacifica, CA, United States
Somers, Todd, Montara, CA, United States
Webb, Rob, Moss Beach, CA, United States
Robarge, Kirk, San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5565449		19961015
APPLICATION INFO.:	US 1995-452479		19950526 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-70457, filed on 8 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-866931, filed on 10 Apr 1992, now patented, Pat. No. US 5250679 which is a continuation-in-part of Ser. No. US 1991-781477, filed on 18 Oct 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bond, Robert T.		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1,2		
LINE COUNT:	13455		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 7 USPATFULL on STN
TI Ras farnesyl transferase inhibitors
AB Benzodiazepine derivatives are disclosed that act as potent inhibitors
of ras farnesyl:protein transferase. Pharmaceutical compositions
containing these benzodiazepines are provided for treatment of diseases
for which inhibition of the ras farnesyl:protein transferase is
indicated. Also disclosed are benzazepines of the following general
formula (II) having similar utility as the aforementioned
benzodiazepines: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:58332 USPATFULL
 TITLE: Ras farnesyl transferase inhibitors
 INVENTOR(S): Marsters, Jr., James C., Oakland, CA, United States
 Brown, Michael S., Dallas, TX, United States
 Crowley, Craig W., Portola Valley, CA, United States
 Goldstein, Joseph L., Dallas, TX, United States
 James, Guy L., Dallas, TX, United States
 McDowell, Robert S., San Francisco, CA, United States
 Oare, David, Belmont, CA, United States
 Rawson, Thomas E., Mountain View, CA, United States
 Reynolds, Mark, So. San Francisco, CA, United States
 Somers, Todd C., Montara, CA, United States
 PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
 (U.S. corporation)
 Board of Regents, The University of Texas System,
 Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 5532359		19960702
APPLICATION INFO.:	US 1994-328595		19941025 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-82202, filed on 24 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61961, filed on 14 May 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Datlow, Philip I.		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	4800		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			